Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CMTX is a nice multi day mover. Up 10% @ 1.76
CTMX—(+25%)—inks REGN drug-discovery collaboration—$30M up-front cash:
https://www.globenewswire.com/news-release/2022/11/17/2558024/37704/en/CytomX-and-Regeneron-Announce-Strategic-Research-Collaboration-in-the-Field-of-Conditional-Bispecific-Therapeutics-for-the-Treatment-of-Cancer.html
Potential for up to $2 billion in research, development, regulatory and sales-based milestones .
Cryptocurrency brokerages Gemini and Genesis are reassuring people that their operations are still solvent after the massive collapse of exchange FTX.
The insolvency of FTX could result in more companies in the industry facing severe liquidity issues, including crypto exchanges and lenders.
Gemini, the exchange founded by the Winklevoss twins, is attempting to calm crypto investors. The exchange said on Wednesday that it would halt withdrawals on its Earn accounts that provide interest. The lending partner for the Earn accounts is Genesis.
Let's go CTMX !!!!!
Agree! Going to stellar heights in upcoming sessions.
CTMX
That's the trump card that will ignite share price big time!
Crude - at a billion MC what happens when Merck and ketruda take a 20% interest?
Ivy League endowment funds, pension plans, and mutual funds all over CMTX.
Tutes will continue to accumulate shares.
CTMX is a great multi-dollars opportunity.
Wow, huge catalysts !!!!!
CTMX
Did a bit of due diligence and reviewed the
quarterly filing and I am still stunned this is
still only 1.60… PRIOR to that unbelievable PR
yesterday …
- only 66 million outstanding shares
- 90 million in cash !!!!?
- zero dilution
- already has a contract with BRISTOL MEYERS
($70 stock, over hundred billion MC)
-already has a contract with ABBVIE
($170 stock, over hundred billion MC)
-revenue generating, 16 m per qtr
and on top of that yesterday’s news with
Regeneron ($700 stock) and CTMX is getting
30 million from Regeneron!!!!!!?
I am not in. Too many potential roadblocks.
A kidney disease drug that seemed to have little likelihood of receiving Food and Drug Administration approval received an unexpected boost late Thursday, when a committee of the agency's outside advisors voted in favor of the proposition that the drug's benefits outweigh its risks.
The drug, Ardelyx's (ARDX) tenapanor, is under consideration for FDA approval as a treatment for elevated levels of serum phosphorus in the blood of chronic kidney disease patients receiving dialysis. The drug is already approved as a treatment for constipation in patients with irritable bowel syndrome, and marketed under the name Ibsrela.
The FDA's advisors voted nine to four in favor of the risk-benefit profile of tenapanor administered alone to treat high serum phosphorus levels, and 10 to two in favor of its risk-benefit profile in combination with a drug known as a phosphate binder.
Investors had attributed low odds to the drug receiving FDA approval, and the agency isn't required to follow the advisory committee's guidance. What's more, given the lengthy and unusual path the drug has taken so far through the FDA's approval process, the path ahead for the drug is complicated, and somewhat hazy.
Still, shares of Ardelyx surged 45% to $1.77 in recent Thursday morning trading, after spiking more than 50% before the market open. The stock saw at least one upgrade Thursday morning.
That upgrade came from Piper Sandler analyst Christopher Raymond, who raised his rating on Ardelyx to Overweight from Neutral. Raymond set a target price of $8, up from his previous target of $3.
"While we found the vote itself remarkable, more meaningful was the fact that the vote was not split along 'party lines,'" Raymond wrote. "Three nephrologists, three cardiologists and both biostatisticians on the panel voted in favor of the monotherapy benefit/risk."
Ardelyx shares were trading at $1.94 before the market opened on Thursday, up from its previous closing price of $1.22. Trading was suspended much, if not all, of the day on Wednesday.
Shares had traded in the $7 to $8 range until July of last year, when the FDA unexpectedly rejected Ardelyx's application for tenapanor's approval, sending the stock down 74% in a single day. At the time, the agency told Ardelyx that while the drug did reduce serum phosphorus levels in the chronic kidney disease patients, the actual effect was "small and of unclear clinical significance."
The rejection took investors by surprise, and analysts suggested that the agency's position was unfair. Piper Sandler's Raymond wrote at the time that the FDA seemed to have "moved the goal posts" by raising questions about the clinical significance at the last minute, after the agency guided the design of Ardelyx's trial.
Ardelyx appealed the decision once and was rejected, but in April of this year, the company said a second appeal had resulted in the FDA agreeing to schedule an advisory committee meeting. The FDA's briefing documents, released on Monday, reiterated the FDA reviewers' questions about the drug's clinical benefit.
"The clinical significance of the magnitude of the treatment effect is unclear," the reviewers wrote in the briefing document. "While there is well established precedent for accepting serum phosphorus as a surrogate endpoint and basis for approval in this therapeutic area, there is no precedent for accepting treatment effects of the magnitude seen in this development program."
Expectations for a new outcome were low going into Thursday's meeting, and the advisors' overwhelming support for the drug's risk-benefit profile, in the face of the agency's skepticism, took analysts by surprise. A positive vote by the advisors, however, doesn't necessarily guarantee FDA approval.
"This is somewhat uncharted territory as it's rare for an appeal to be granted an [advisory committee hearing]; even more rare for the [advisory committee] to resoundingly reject FDA's rationale," Piper Sandler's Raymond wrote.
Now, the FDA's Office of New Drugs, the entity to which Ardelyx had submitted its second appeal, will make a decision within 30 days on that appeal. If the office finds in Ardelyx's favor, the company would then need to resubmit its application for approval of tenapanor. Raymond wrote that he expected approval of the drug in the new indication at the end of next year.
Write to Josh Nathan-Kazis at josh.nathan-kazis@barrons.com
(END) Dow Jones Newswires
$weet RUN !!!!!
Institutions hold less than 1% shares. Along with dilution, why even buy now? Company needs to uplist to Nasdaq . The dilution will drive share price lower.
It doesn't matter! Diluting $250, 000, 000.
SEC S-1 > Ongoing shelf placement > $250M > " This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission (the “SEC”), using a “shelf” registration process. Under this shelf registration process, we may sell any combination of the securities described in this prospectus in one or more offerings up to a total dollar amount of $250,000,000. This prospectus provides you with a general description of the securities we may offer. Each time we sell securities, we will provide a prospectus supplement that will contain specific information about the securities being offered and the terms of that offering. The prospectus supplement may also add to, update or change information contained in this prospectus.
Aaron Judge will pay 55% tax > NY city, state, & Fed. taxes. Steinbrener will need more than NWBO shares.
SEC S-1 > Ongoing shelf placement > $250M > " This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission (the “SEC”), using a “shelf” registration process. Under this shelf registration process, we may sell any combination of the securities described in this prospectus in one or more offerings up to a total dollar amount of $250,000,000. This prospectus provides you with a general description of the securities we may offer. Each time we sell securities, we will provide a prospectus supplement that will contain specific information about the securities being offered and the terms of that offering. The prospectus supplement may also add to, update or change information contained in this prospectus.
"The Company believes this is the first time in nearly 20 years that a Phase III trial of a systemic treatment has shown such survival extension in newly diagnosed glioblastoma, and the first time in nearly 30 years that a Phase III trial of any type of treatment has shown such survival extension in recurrent glioblastoma."
BOOM > $$$$$
Yup, all good catalysts!
The racking up of ongoing corporate revenues taking TPTW to the Nasdaq Exchange next year.
Our acquisition of IST is huge > Revenues + >>>>> "has been awarded its third 3-year contract renewal valued at $2,862,435.00 with the U.S. Army Contracting Command, Stryker Division. Information Systems Technology (IST) will support the Initial Fielding of Stryker vehicles, Army Training and Education. The company will also create, maintain and track all logistical programmatic-related issues about the fielding, deployment, retrofitting, and prep for reset/reissue of Stryker vehicles."
"TPT Global Tech has been planning to enter the government contracting space for some time now as part of our overall strategic plan. This is the first of a planned series of federal contracts the company is expecting."
Agree!
News> PARSIPPANY, N.J.--(BUSINESS WIRE)--IVERIC bio, Inc. (Nasdaq: ISEE) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for avacincaptad pegol (ACP, also known as Zimura®), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to Age-Related Macular Degeneration (AMD). To date, ACP is the first and only investigational therapy to receive Breakthrough Therapy designation status for this indication, which was granted based on the 12-month pre-specified primary endpoint data in the GATHER1 and GATHER2 pivotal clinical trials.
“In both GATHER1 and GATHER2, avacincaptad pegol consistently showed a treatment effect with the first measurement at month 6 that was persistent and continued to increase over time, with observed efficacy rates of up to 35%”
Tweet this
Breakthrough Therapy designation is designed to accelerate the development and regulatory review of potential new medicines that are intended to treat a serious condition and address a significant unmet medical need. The new medicine needs to show preliminary clinical evidence that the drug may demonstrate substantial improvement in effectiveness or safety over available therapies on a clinically significant endpoint and in general, should show a clear advantage.1
“We believe this Breakthrough designation reflects the fact that both GATHER1 and GATHER2 met their primary endpoint with a safety profile that meets the stringent criteria required,” said Glenn P. Sblendorio, Chief Executive Officer of Iveric Bio. “We are now focused on the execution of our full NDA submission and launch preparation, with the possibility of being first to market. We look forward to working collaboratively with the FDA to expedite the review timeline for avacincaptad pegol and to potentially bringing a new therapy to AMD patients impacted by GA.”
Recently, Iveric Bio announced the submission of the first part of its New Drug Application (NDA) for rolling review, which included the full clinical data package from the GATHER1 and GATHER2 pivotal trials. The company is on track to complete the final part of the NDA submission by the end of this year.
“In both GATHER1 and GATHER2, avacincaptad pegol consistently showed a treatment effect with the first measurement at month 6 that was persistent and continued to increase over time, with observed efficacy rates of up to 35%,” said Pravin U. Dugel, MD, President of Iveric Bio. “We believe ACP has the potential to safely and effectively preserve central vision by saving photoreceptor cells for patients living with this life-changing disease that leads to irreversible blindness.”
The FDA’s Breakthrough Therapy designation decision was based on the 12-month primary efficacy endpoint data from the GATHER1 and GATHER2 pivotal studies which evaluated the safety and efficacy of ACP in patients with GA located inside and/or outside of the clinical fovea. Per the special protocol assessment (SPA) agreement for GATHER2, the FDA required the mean rate of growth (slope) in GA area from baseline to month 12. These results showed a significant treatment difference of 35% (p=0.0050; GATHER1) and 18% (p= 0.0039, GATHER2) compared to sham using observed (non-transformed) data; and 28% (p=0.0063; GATHER1) and 14% (p= 0.0064; GATHER2) using square root transformation. In both GATHER1 and GATHER2 there were no events of serious intraocular inflammation, vasculitis, or endophthalmitis.
About Geographic Atrophy
Age-related macular degeneration (AMD) is the major cause of moderate and severe loss of central vision in aging adults, affecting both eyes in the majority of patients. The macula is a small area in the central portion of the retina responsible for central vision. As AMD progresses, the loss of retinal cells and the underlying blood vessels in the macula results in marked thinning and/or atrophy of retinal tissue. Geographic atrophy, the advanced stage of AMD, leads to further irreversible loss of vision in these patients. There are currently no U.S. FDA or European Medicines Agency (EMA) approved treatment options available for patients with geographic atrophy secondary to AMD.
Yup, definitely a great $$$$$ opportunity.
Let's go TPTW !!!!!
We're getting new long haul investors each day. > $$$$$
Also, the quality and quanity of government revenues generated from recent Multi-million $$$$$ contracts is sending TPTW shares much higher.
Soon we hit $1.00 > MICT is a great $$$$$ opportunity.
Another $tellar close. Patience pays off, especially with exponential revenue generation. Keep those nice Multi-million $$$$$ contracts coming!
TPTW
Let's go TPTW !!!!! > Another 80% + day today!
A book is baring all on Joe Biden’s love for stripping down in the pool.
In “The First Family Detail: Secret Service Agents Reveal Hidden Lives of the Presidents,” written by former Wall Street Journal reporter Ronald Kessler, readers get a look inside the private lives of politicians, told by the Secret Service agents assigned to protect them.
“Agents say that, whether at the vice president’s residence or at his home in Delaware, Biden has a habit of swimming in his pool nude,” Kessler wrote, according to the New York Daily News.
Female Secret Service agents found his skinny dipping to be “offensive.”
This is Kessler’s 20th non-fiction book. For “The First Family Detail” Kessler interviewed unnamed Secret Service agents about their experiences with some of the nation’s most powerful people.
“The First Family Detail” describes the vice president’s desire to be seen as a “regular Joe,” but says that agents find that “being assigned to his detail is considered the second worst assignment in the Secret Service.”
FILED UNDER: JOE BIDEN, JOE BIDEN 2020, BOOKS, JOURNALISM, SECRET SERVICE
POLITICO.
The photo, published by The Associated Press, was taken in March 2016 and shows people demonstrating against then-president Dilma Rousseff over allegations of corruption.
THE FACTS: As supporters of President Jair Bolsonaro continue to protest his defeat by Luiz Inácio Lula da Silva in the country’s recent election, a 2016 photo showing a large protest near the National Congress in Brasília has circulated on social media with false claims tying it to Bolsonaro’s loss.
The photo shows a massive crowd of people filling a broad street, many carrying balloons or Brazilian flags. The towers of the National Congress building can be seen in the distance, to the left of the street.
“Brazil is Doing This Correct RISE UP AGAINST #voterfraud. Americans need to STAND UP AGAINST STOLEN ELECTIONS JUST LIKE BRAZIL IS DOING Nothing is going to change unless we rise up,” reads the post’s caption.
AP photographer Eraldo Peres took the photo on March 13, 2016. The protesters in the photo took to the streets to demand Rousseff’s impeachment as part of a nationwide day of protests. According to AP reporting at the time, the demonstrations took place in around 200 cities and towns across Brazil. Rousseff was removed from office in August 2016, amid accusations of fiscal mismanagement and a corruption investigation involving state-run oil giant Petrobras.
Last month, da Silva beat Bolsonaro in one of the country’s tightest presidential races, with just 50.9% of the votes. Although the Bolsonaro administration has not opposed the transition of power, he has yet to concede or congratulate da Silva, the AP reported. Many of his supporters have refused to accept his defeat, citing purported voter fraud. Brazil’s defense ministry released a report last week stating that it found no evidence of fraud in the vote counting.
___
This is part of AP’s effort to address widely shared misinformation, including work with outside companies and organizations to add factual context to misleading content that is circulating online. Learn more about fact-checking at AP.
ADVERTISEMENT
PromotedYou May Like
The 25 Best Songs Ever Recorded Ranked In Order
Promoted: thedelite.com
Banned For 84 Years; New York Approves New Pain Relief ‘Drops’
Promoted: Health Headlines
Put Dish Soap On Your Glasses Every Morning, Here's Why
Promoted: SheBudgets.com
Unsold 2020 Nissan Rogues Now Almost Being Given Away (See Prices)
Promoted: Nissan Rogue
by Taboola
ADVERTISEMENT
PAID FOR BY QUALIFY MEDICARE
If You Have Medicare Parts A & B, Make Sure To Read This!
Those on Medicare should check this before the end of the month
Qualify medicare
If You Have Medicare Parts A & B, Make Sure To Read This!
Ad Content
If You Have Medicare Parts A & B, Make Sure To Read This!
Qualify medicare
Here Are 23+ Hottest Gifts Of 2022
TrendingGifts
Here's The Average Price Of A Gutter Protection
Search Gutter Guards
Think Dental Implants Are Expensive? Think Again! (See Prices)
Search Dental Implants
Search For Data Storage In The Cloud
Search Cloud Storage
50 Insanely Cool Gadgets You'll Regret Not Getting Before They Sell Out
SmartLifestyleTrends
Ad Content
Those On Medicare Parts A & B, Check This Today!
Promoted: Qualify medicare
They're selling like crazy. Everybody wants them.
Promoted: LIfehackin
15 Actors That Hollywood Banned For Life
Promoted: YourBump
Republican Kari Lake narrows gap in Arizona governor race
PHOENIX (AP) — The nation's last undecided race for governor got even closer Sunday as Democrat Katie Hobbs' lead shrank against Republican Kari Lake in the race to lead Arizona, but it was too early to call.
November 13, 2022
Ad Content
Kristian Alfonso Is Now Unrecognizable After Her Recent Transformation
Wordsa
Need Dental Implants But Have No Money?
Search Dental Implants
Buffalo: Unsold Never-Used Cars Now Almost Being Given Away: See Prices
SUV Deals | Search Ads
Less Space Will Not Be Any Problem To Organize Your Clothings Now With.
Storage Bag
Put A Bottle On Your Car Tire When Parking Alone
SheBudgets.com
30 Oldest Living Hollywood Actors
Boite A Scoop
Ad Content
Tom Brady’s Ex Finally Speaks Out About Gisele
Promoted: Bedtimez
Gwen Stefani's No Makeup Photo: Her Real Face Is Quite Different
Promoted: Doctor Report
New York Approves New ‘Chew’ For Arthritis & Pain Sufferers
Promoted: Health Headlines
Man who threatened plane crash into Walmart dies in prison
JACKSON, Miss. (AP) — An airport worker who flew a stolen twin-engine plane erratically over north Mississippi
an hour ago
AP NEWS
Top Stories
Video
Contact Us
Accessibility Statement
Cookie Settings
DOWNLOAD AP NEWS
Connect with the definitive source for global and local news
MORE FROM AP
ap.org
AP Insights
AP Definitive Source Blog
AP Images Spotlight
AP Explore
AP Books
AP Stylebook
FOLLOW AP
THE ASSOCIATED PRESS
About
Contact
Customer Support
Careers
Terms & Conditions
Privacy
All contents © copyright 2022 The Associated Press. All rights reserved.
$olid Session! TPTW @ .83 up 80% > closing bell.
$22,000 for Taylor Swift upcoming concert tickets. Hold FSRD shares > your profits will be more than (1) Swift ticket.
While presale tickets were initially only open to Swift fans selected as “verified fans” – a system set up to deter bots and scalpers – some tickets were already being listed on resale sites such as StubHub for as much as US$22,700 (£19,100, A$33,500) each.
Ticket sales for west coast shows were delayed by three hours to help ease pressure on Ticketmaster. Another presale, for Capital One credit cardholders, was postponed from Tuesday to Wednesday.
$22,000 for Taylor Swift upcoming concert tickets. Hold MICT shares > your profits will be more than (1) Swift ticket.
While presale tickets were initially only open to Swift fans selected as “verified fans” – a system set up to deter bots and scalpers – some tickets were already being listed on resale sites such as StubHub for as much as US$22,700 (£19,100, A$33,500) each.
Ticket sales for west coast shows were delayed by three hours to help ease pressure on Ticketmaster. Another presale, for Capital One credit cardholders, was postponed from Tuesday to Wednesday.
$22,000 for Taylor Swift upcoming concert tickets. Hold TPTW shares > your profits will be more than (1) Swift ticket.
While presale tickets were initially only open to Swift fans selected as “verified fans” – a system set up to deter bots and scalpers – some tickets were already being listed on resale sites such as StubHub for as much as US$22,700 (£19,100, A$33,500) each.
Ticket sales for west coast shows were delayed by three hours to help ease pressure on Ticketmaster. Another presale, for Capital One credit cardholders, was postponed from Tuesday to Wednesday.
$22,000 for Taylor Swift upcoming concert tickets. (1) ticket is worth more than (1) bitcoin.
While presale tickets were initially only open to Swift fans selected as “verified fans” – a system set up to deter bots and scalpers – some tickets were already being listed on resale sites such as StubHub for as much as US$22,700 (£19,100, A$33,500) each.
Ticket sales for west coast shows were delayed by three hours to help ease pressure on Ticketmaster. Another presale, for Capital One credit cardholders, was postponed from Tuesday to Wednesday.
"I take this opportunity to thank Mr. Chantengco and the whole Black Pearl Investments team for their trust, faith, and confidence in TPT Global Tech's smart city vision and objectives," said Mr. Thomas.
Mr. Thomas continued, "We are emboldened to have BPI involved with us for additional projects, primarily in the US, which we plan on initiating as soon as the Tuskegee project is underway. TPT Global Tech is focused on building strong business corridors within the US and with other partner countries such as India which will help support our objective to strengthen domestic industries, attract global companies, create jobs, improve regional infrastructure including schools and universities, as well as developing economic opportunities for Americans."